Global Antimicrobial Resistance Innovation Fund (GAMRIF) - New Antibiotic for Drug-Resistant Gonorrhoea with GARDP
Project disclaimer
Description
The Global Antibiotic Research & Development Partnership (GARDP) is a non-profit product development partnership. It is a research and development initiative addressing global public health needs by developing, delivering and assuring sustainable access of new or improved antibiotic treatments. UK Department of Health and Social Care (DHSC) funding through the Global AMR Innovation Fund (GAMRIF) will support GARDP’s programme on sexually transmitted infections (STI), specifically focusing on the development of a new antibiotic for drug-resistant gonorrhoea.
Location
The country, countries or regions that benefit from this Programme.
Status Implementation
The current stage of the Programme, consistent with the International Aid Transparency Initiative's (IATI) classifications.
Programme Spend
Programme budget and spend to date, as per the amounts loaded in financial system(s), and for which procurement has been finalised.
Participating Organisation(s)
Help with participating organisations
Accountable:Organisation responsible for oversight of the activity
Extending: Organisation that manages the budget on behalf of the funding organisation.
Funding: Organisation which provides funds.
Implementing: Organisations implementing the activity.
- Accountable
- Funding
- Implementing
Sectors
Sector groups as a percentage of total Programme budget according to the OECD Development Assistance Committee (DAC) classifications.
Budget
A comparison across financial years of forecast budget and spend to date on the Programme.
Download IATI Data for GB-GOV-10-GAMRIF-WP6-GARDP-2019-2022
Programme data last updated on 29/06/2021